Companies
Vertex Pharmaceuticals
BiotechnologyBoston, MassachusettsVRTXAbout 6,400 employees
More about Vertex Pharmaceuticals
Biotechnology company that makes medicines for cystic fibrosis, sickle cell disease, beta thalassemia and acute pain
Revenue
$12.0B
Fiscal 2025, up 9%
Employees
About 6,400
As of December 2025
Stock
VRTX
Nasdaq
Headquarters
Boston, Massachusetts
CEO
Reshma Kewalramani
Since April 2020
BrandsTrikafta/Kaftrio, Alyftrek, Casgevy, Journavx
Current strategyGrowing its cystic fibrosis franchise while expanding Casgevy and Journavx and preparing to launch povetacicept for IgA nephropathy
CompetitorsRegeneron, Amgen, Gilead Sciences
Related companiesRegeneron PharmaceuticalsAmgenGilead Sciences
Checked October 11, 2026 · Sources: businesswire.com, sec.gov
No source-backed updates for Vertex Pharmaceuticals yet. They appear here when a public report or filing covers the company.
No one has posted about Vertex Pharmaceuticals yet. Be the first to post ›
Follow Vertex Pharmaceuticals in a feed reader, no account needed: RSS feed